With Shire, Did AbbVie Count Its Chickens Before They Hatched?

AbbVie acquires Shire in a $54 billion transaction.

Jul 18, 2014 at 7:10PM

Stocks rebounded from Thursday's 1.2% "sell-off" today as heightened geopolitical risk in the Ukraine and Israel could not hold investors' attention. Yesterday's decline was substantial by the standards of the past several months of ultra-low volatility, but unremarkable in a broader context. The benchmark S&P 500 rose 1% on Friday, with the narrower Dow Jones Industrial Average (DJINDICES:^DJI) up 0.7%. The technology-heavy Nasdaq Composite Index (NASDAQINDEX:^IXIC) finished up 1.6%. In company-specific news, AbbVie (NYSE:ABBV) is taking home the prize that is Ireland-based Shire (NASDAQ:SHPG) in a $54 billion deal, or perhaps it would be better said that part of the prize is being able to switch homes (see story below.)


Source: Wikimedia Commons.

On Monday, I wrote that AbbVie's takeover of Shire was going to happen, after Shire had announced that it was happy with the price of 53.20 pounds per share that AbbVie had come up with -- on its fifth offer, no less! Apparently, the two companies were able to successfully negotiate "the other terms of the offer," as they announced this morning that they would combine in a deal valued at $54 billion. But there's a third party that the two companies may yet have to reckon with -- the U.S. Treasury.

One of the reasons why AbbVie was able to raise its offer multiple times was because of the value of a particular feature of the deal that will enable it to switch its tax domicile to the U.K., under a process known as "tax inversion," thereby substantially lowering its tax rate. Shire is based in Ireland, and registered on the Channel Island of Jersey.

In the Powerpoint presentation [opens a PDF document] that AbbVie has put together to sell the transaction to shareholders, the company boasts: "AbbVie expects the effective tax rate for New AbbVie to approximate 13% by 2016; the new tax structure will provide AbbVie with flexible access to its global cash flows."

That 13% rate would represent a near halving of AbbVie's current tax rate – a hugely valuable improvement. The second clause refers to the fact that, post-acquisition, AbbVie will be able to access its worldwide profits without having to pay a 35% "repatriation" tax to the U.S. Treasury.

However, AbbVie may be counting its tax inversion before it's hatched. Writing to leaders of the congressional tax-writing committees on Tuesday, Treasury Secretary Jack Lew urged lawmakers to enact legislation that would curtail tax inversions. AbbVie expects the acquisition of Shire to close during the fourth quarter.

While the Congress does not appear to share the Obama administration's sense of urgency in regard to passing such legislation, it could still bear on this transaction if it were passed with retroactive effect. In his letter, Mr. Lew recommended making the law retroactive to May 2014. AbbVie shareholders had better hope the company left itself a margin of safety in accounting for the tax benefits of the deal.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There's a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns, you'll need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. CLICK HERE NOW.

Alex Dumortier, CFA has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers